CHD, orthostatic hypotension; patients w/ excessive haemodynamic reaction on previous α1
-blocker treatment & receiving antihypertensives; swallowing disorders eg, stenosing oesophageal changes or neurological disorders accompanied by impaired oesophageal motility. Intraoperative floppy iris syndrome (IFIS). Changes in breast tissue eg, lumps or nipple discharge; male breast cancer. Monitor for acute/chronic urinary retention in patients w/ large residual urinary vol &/or severely impaired urine flow. Perform digital rectal exam & PSA level for prostate cancer detection. Not to be co-administered w/ potent CYP3A4 inhibitors eg, ketoconazole, itraconazole, voriconazole, clarithromycin, indinavir, nelfinavir, ritonavir, saquinavir. Co-administration w/ moderate CYP3A4 inhibitors eg, erythromycin, fluconazole, verapamil, diltiazem. May affect ability to drive & use machines. Mild to moderate hepatic & severe renal impairment. Avoid use during pregnancy. Lactation. Not indicated in patients ≤21 yr.